focus -WSS

focus

author：comprehensive 2025-09-06 05:03:32 - browse：9

Empty biotech lab with no people and green benches and cabinets. -- biotech coverage from STAT — Adobe

Demand for new lab space has plummeted by more than half since the end of 2021, and life science vacancy rates are the highest they’ve been in a decade amid the biotech industry’s ongoing downturn, according to a report released Tuesday by Jones Lang LaSalle, a commercial real estate services company

Tenant demand, measured by the total amount of new space that companies are looking to lease, dropped from 25.3 million square feet at the end of 2021 to 10.1 million square feet by the second quarter of this year across eight top life science markets: Boston, the Bay Area, San Diego, Raleigh-Durham, Philadelphia, Seattle, Los Angeles, and the Washington, D.C., area.

The real estate numbers presented in JLL’s annual life sciences report are yet another sign that the biotech industry, which outperformed the broader market for years, is in the midst of a slowdown. Lab space is increasingly going unused amid a supply glut, and more companies are looking to sublease space. Real estate observers say there are some signs these trends could turn around in the next year or two, though that is far from certain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： An innovative path out of biotech’s “valley of death”

focus

WSS

The biotech scorecard for Q4: 16 stock

After John Oliver segment, STAT readers share their opioid

The United States is paying nearly triple for new Covid vaccines

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

Some of the ways extreme heat will change life as we know it

Setback for rare diseases as Taysha Gene Therapies pulls back

leisure time

focus

leisure time

Moonlake's readout produced a cash windfall. Risks remain

What we owe ALS patients — and why one company fell short

How one medical school became remarkably diverse

CRISPR base editing slashes cholesterol levels in monkeys

Hollywood unions extend contract negotiations for actors

Setback for rare diseases as Taysha Gene Therapies pulls back

As demand for Covid shots wanes, Moderna seeks its next success

Will an HIV vaccine ever be a reality?

Apple is now the first public company to be valued at $3 trillion

Will an HIV vaccine ever be a reality?

focus

Nobel honors Karikó and Weissman's enduring partnership

Study points to new risk in gene therapy death of Terry Horgan

Who are the detained American citizens released from prison in Iran?

Kim Kardashian sparks debate on benefits of full

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

CDC overhauls leadership of center that led response to Covid

explore

focus

entertainment

hotspot